245 FIRST STREET, CAMBRIDGE, MA
Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
.2AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT
Investor Presentation
Announces Establishment of Rare Kidney Disease Pipeline
Amendment to License Agreement with MEDICE for Vafseo Supply
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Provides Update on Vafseo for Non-Dialysis Patients
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Definitive Revised Proxy Statement
Confidential Treatment Order